201 related articles for article (PubMed ID: 29187381)
1. CRRL269: a novel designer and renal-enhancing pGC-A peptide activator.
Chen Y; Harty GJ; Huntley BK; Iyer SR; Heublein DM; Harders GE; Meems L; Pan S; Sangaralingham SJ; Ichiki T; Burnett JC
Am J Physiol Regul Integr Comp Physiol; 2018 Mar; 314(3):R407-R414. PubMed ID: 29187381
[TBL] [Abstract][Full Text] [Related]
2. CRRL269.
Chen Y; Harty GJ; Zheng Y; Iyer SR; Sugihara S; Sangaralingham SJ; Ichiki T; Grande JP; Lee HC; Wang X; Burnett JC
Circ Res; 2019 May; 124(10):1462-1472. PubMed ID: 30929579
[TBL] [Abstract][Full Text] [Related]
3. Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions.
Lee CY; Huntley BK; McCormick DJ; Ichiki T; Sangaralingham SJ; Lisy O; Burnett JC
Eur Heart J Cardiovasc Pharmacother; 2016 Apr; 2(2):98-105. PubMed ID: 27340557
[TBL] [Abstract][Full Text] [Related]
4. Cardiovascular and renal effect of CNAAC: An innovatively designed natriuretic peptide.
Zhang S; Geng X; Zhao L; Li J; Tian F; Wang Y; Fan R; Feng N; Liu J; Cheng L; Pei J
Eur J Pharmacol; 2015 Aug; 761():180-8. PubMed ID: 25979857
[TBL] [Abstract][Full Text] [Related]
5. C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts.
Chen Y; Zheng Y; Iyer SR; Harders GE; Pan S; Chen HH; Ichiki T; Burnett JC; Sangaralingham SJ
J Mol Cell Cardiol; 2019 May; 130():140-150. PubMed ID: 30954448
[TBL] [Abstract][Full Text] [Related]
6. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
[TBL] [Abstract][Full Text] [Related]
7. Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure.
Chen HH; Cataliotti A; Schirger JA; Martin FL; Burnett JC
Am J Physiol Regul Integr Comp Physiol; 2005 May; 288(5):R1093-7. PubMed ID: 15627648
[TBL] [Abstract][Full Text] [Related]
8. Natriuretic peptide analogues with distinct vasodilatory or renal activity: integrated effects in health and experimental heart failure.
Rademaker MT; Scott NJA; Koh CY; Kini RM; Richards AM
Cardiovasc Res; 2021 Jan; 117(2):508-519. PubMed ID: 32167565
[TBL] [Abstract][Full Text] [Related]
9. Comparison of renal actions of urodilatin and atrial natriuretic peptide.
Hildebrandt DA; Mizelle HL; Brands MW; Hall JE
Am J Physiol; 1992 Mar; 262(3 Pt 2):R395-9. PubMed ID: 1313650
[TBL] [Abstract][Full Text] [Related]
10. Evidence for Angiotensin II as a Naturally Existing Suppressor for the Guanylyl Cyclase A Receptor and Cyclic GMP Generation.
Ma X; Iyer SR; Ma X; Reginauld SH; Chen Y; Pan S; Zheng Y; Moroni DG; Yu Y; Zhang L; Cannone V; Chen HH; Ferrario CM; Sangaralingham SJ; Burnett JC
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239899
[TBL] [Abstract][Full Text] [Related]
11. Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides.
Ichiki T; Huntley BK; Sangaralingham SJ; Burnett JC
JACC Heart Fail; 2015 Sep; 3(9):715-23. PubMed ID: 26362447
[TBL] [Abstract][Full Text] [Related]
12. Particulate Guanylyl Cyclase A/cGMP Signaling Pathway in the Kidney: Physiologic and Therapeutic Indications.
Chen Y; Burnett JC
Int J Mol Sci; 2018 Mar; 19(4):. PubMed ID: 29584705
[TBL] [Abstract][Full Text] [Related]
13. Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide.
Meems LMG; Andersen IA; Pan S; Harty G; Chen Y; Zheng Y; Harders GE; Ichiki T; Heublein DM; Iyer SR; Sangaralingham SJ; McCormick DJ; Burnett JC
Hypertension; 2019 Apr; 73(4):900-909. PubMed ID: 30798663
[TBL] [Abstract][Full Text] [Related]
14. Renal effects of urodilatin in healthy subjects are independent of blockade of the cyclooxygenase and angiotensin II receptor.
Carstens J; Pedersen EB
Scand J Clin Lab Invest; 2008; 68(1):2-10. PubMed ID: 17852806
[TBL] [Abstract][Full Text] [Related]
15. The renal paracrine peptide system--possible urologic implications of urodilatin.
Meyer M; Stief CG; Becker AJ; Truss MC; Taher A; Jonas U; Forssmann WG
World J Urol; 1996; 14(6):375-9. PubMed ID: 8986039
[TBL] [Abstract][Full Text] [Related]
16. Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism.
Borgeson DD; Stevens TL; Heublein DM; Matsuda Y; Burnett JC
Clin Sci (Lond); 1998 Aug; 95(2):195-202. PubMed ID: 9680502
[TBL] [Abstract][Full Text] [Related]
17. Dendroaspis natriuretic peptide and the designer natriuretic peptide, CD-NP, are resistant to proteolytic inactivation.
Dickey DM; Potter LR
J Mol Cell Cardiol; 2011 Jul; 51(1):67-71. PubMed ID: 21459096
[TBL] [Abstract][Full Text] [Related]
18. Renal effects of a urodilatin infusion in patients with liver cirrhosis, with and without ascites.
Carstens J; Greisen J; Jensen KT; Vilstrup H; Pedersen EB
J Am Soc Nephrol; 1998 Aug; 9(8):1489-98. PubMed ID: 9697672
[TBL] [Abstract][Full Text] [Related]
19. A novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertension.
McKie PM; Cataliotti A; Boerrigter G; Chen HH; Sangaralingham SJ; Martin FL; Ichiki T; Burnett JC
Hypertension; 2010 Dec; 56(6):1152-9. PubMed ID: 20975033
[TBL] [Abstract][Full Text] [Related]
20. Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure.
Rademaker MT; Charles CJ; Kosoglou T; Protter AA; Espiner EA; Nicholls MG; Richards AM
Am J Physiol; 1997 Nov; 273(5):H2372-9. PubMed ID: 9374774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
